Daniel B Schmolze

List of Publications by Year in Descending Order

42 papers	**601** citations
13 h-index	**24** g-index
48 ext. papers	**882** ext. citations
5.8 avg, IF	**3.82** L-index

#	Paper	IF	Citations
42	Molecular Imaging of HER2 in Patient Tissues with Touch Prep-Quantitative Single Molecule Localization Microscopy.. *Methods in Molecular Biology*, **2022**, 2394, 231-248	1.4	
41	Stressed out and fed up: The effect of stress on maternal feeding behaviors and the moderating role of executive function. *Appetite*, **2022**, 168, 105762	4.5	
40	Hyperthermic Intraperitoneal Chemotherapy-Induced Molecular Changes in Humans Validate Preclinical Data in Ovarian Cancer.. *JCO Precision Oncology*, **2022**, 6, e2100239	3.6	1
39	Molecular Assessment of HER2 to Identify Signatures Associated with Therapy Response in HER2-Positive Breast Cancer. *Cancers*, **2022**, 14, 2795	6.6	0
38	Quantitative Impact of the 2018 American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) Practice Guideline Update on Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: A Systematic Analysis. *Archives of Pathology and Laboratory Medicine*, **2021**, 145, 887-890	5	0
37	MicroRNA Regulation of T-Cell Exhaustion in Cutaneous T Cell Lymphoma. *Journal of Investigative Dermatology*, **2021**,	4.3	3
36	Raman spectroscopy and artificial intelligence to predict the Bayesian probability of breast cancer. *Scientific Reports*, **2021**, 11, 6482	4.9	6
35	Pre-existing effector T-cell levels and augmented myeloid cell composition denote response to CDK4/6 inhibitor palbociclib and pembrolizumab in hormone receptor-positive metastatic breast cancer **2021**, 9,		5
34	Spatial distribution of B cells and lymphocyte clusters as a predictor of triple-negative breast cancer outcome. *Npj Breast Cancer*, **2021**, 7, 84	7.8	2
33	Phase II Trial of Neoadjuvant Carboplatin and Nab-Paclitaxel in Patients with Triple-Negative Breast Cancer. *Oncologist*, **2021**, 26, e382-e393	5.7	11
32	A Phase II Clinical Trial of Pembrolizumab and Enobosarm in Patients with Androgen Receptor-Positive Metastatic Triple-Negative Breast Cancer. *Oncologist*, **2021**, 26, 99-e217	5.7	12
31	Physics approaches to the spatial distribution of immune cells in tumors. *Reports on Progress in Physics*, **2021**, 84, 022601	14.4	4
30	Phase I/II trial of palbociclib, pembrolizumab and letrozole in patients with hormone receptor-positive metastatic breast cancer. *European Journal of Cancer*, **2021**, 154, 11-20	7.5	6
29	Performance of enhancement on brain MRI for identifying HER2 overexpression in breast cancer brain metastases. *European Journal of Radiology*, **2021**, 144, 109948	4.7	0
28	Multi-panel immunofluorescence analysis of tumor infiltrating lymphocytes in triple negative breast cancer: Evolution of tumor immune profiles and patient prognosis. *PLoS ONE*, **2020**, 15, e0229955	3.7	10
27	Occupancy and Fractal Dimension Analyses of the Spatial Distribution of Cytotoxic (CD8+) T Cells Infiltrating the Tumor Microenvironment in Triple Negative Breast Cancer. *Biophysical Reviews and Letters*, **2020**, 15, 83-98	1.2	3
26	Clinical vs genomic risks in breast cancer in 2019: Breast pathologist's appellate review of the controversial results from TAILORx trial. *Breast Journal*, **2020**, 26, 1447-1448	1.2	

25	Comprehensive Profiling of Poor-Risk Paired Primary and Recurrent Triple-Negative Breast Cancers Reveals Immune Phenotype Shifts. *Clinical Cancer Research*, **2020**, 26, 657-668	12.9	39
24	Accuracy of gross intraoperative margin assessment for breast cancer: experience since the SSO-ASTRO margin consensus guidelines. *Scientific Reports*, **2020**, 10, 17344	4.9	9
23	Towards integration of Cu-DOTA-trastuzumab PET-CT and MRI with mathematical modeling to predict response to neoadjuvant therapy in HER2 + breast cancer. *Scientific Reports*, **2020**, 10, 20518	4.9	11
22	Leiomyoadenomatoid Tumor of Epididymis: A Variant of Adenomatoid Tumor. *Annals of Clinical and Laboratory Science*, **2020**, 50, 813-817	0.9	2
21	Pathway activity profiling of growth factor receptor network and stemness pathways differentiates metaplastic breast cancer histological subtypes. *BMC Cancer*, **2019**, 19, 881	4.8	8
20	Identification of Tissue-Specific DNA Methylation Signatures for Thyroid Nodule Diagnostics. *Clinical Cancer Research*, **2019**, 25, 544-551	12.9	19
19	Connecting blood and intratumoral T cell activity in predicting future relapse in breast cancer. *Nature Immunology*, **2019**, 20, 1220-1230	19.1	61
18	Raman Spectroscopy for Rapid Evaluation of Surgical Margins during Breast Cancer Lumpectomy. *Scientific Reports*, **2019**, 9, 14639	4.9	31
17	Mutation and immune profiling of metaplastic breast cancer: Correlation with survival. *PLoS ONE*, **2019**, 14, e0224726	3.7	17
16	Phase I clinical trial of the combination of eribulin and everolimus in patients with metastatic triple-negative breast cancer. *Breast Cancer Research*, **2019**, 21, 119	8.3	16
15	An Automatable Method for Determining Adequacy of Thyroid Fine-Needle Aspiration Samples. *Archives of Pathology and Laboratory Medicine*, **2019**, 143, 1084-1088	5	0
14	Dual mTOR Kinase Inhibitor MLN0128 Sensitizes HR/HER2 Breast Cancer Patient-Derived Xenografts to Trastuzumab or Fulvestrant. *Clinical Cancer Research*, **2018**, 24, 395-406	12.9	10
13	[Regular Paper] MVPNets: Multi-viewing Path Deep Learning Neural Networks for Magnification Invariant Diagnosis in Breast Cancer **2018**,		5
12	Single molecule localization microscopy coupled with touch preparation for the quantification of trastuzumab-bound HER2. *Scientific Reports*, **2018**, 8, 15154	4.9	15
11	Crowdsourcing scoring of immunohistochemistry images: Evaluating Performance of the Crowd and an Automated Computational Method. *Scientific Reports*, **2017**, 7, 43286	4.9	20
10	Complete regression of cutaneous metastases with systemic immune response in a patient with triple negative breast cancer receiving p53MVA vaccine with pembrolizumab. *OncoImmunology*, **2017**, 6, e1363138	7.2	11
9	Using Point of Care Glucose Meters in the Critically Ill. *Point of Care*, **2016**, 15, 137-143	0.4	3
8	A 63-Year-Old Man With Rapidly Progressive Dementia. *Clinical Infectious Diseases*, **2016**, 63, 138-9	11.6	4

7	EMDomics: a robust and powerful method for the identification of genes differentially expressed between heterogeneous classes. *Bioinformatics*, **2016**, 32, 533-41	7.2	32
6	Direct comparison between confocal and multiphoton microscopy for rapid histopathological evaluation of unfixed human breast tissue. *Journal of Biomedical Optics*, **2016**, 21, 126021	3.5	19
5	Assessment of breast pathologies using nonlinear microscopy. *Proceedings of the National Academy of Sciences of the United States of America*, **2014**, 111, 15304-9	11.5	119
4	Characterization and analysis of the composition and dynamics of the mammalian riboproteome. *Cell Reports*, **2013**, 4, 1276-87	10.6	43
3	Value of additional level sections in the evaluation of lymph nodes for endometrial carcinoma staging. *American Journal of Clinical Pathology*, **2013**, 140, 516-8	1.9	5
2	Advances in microscopy techniques. *Archives of Pathology and Laboratory Medicine*, **2011**, 135, 255-63	5	37
1	Fractal dimension, occupancy and hotspot analyses of B cell spatial distribution predict clinical outcome in breast cancer		2